165 related articles for article (PubMed ID: 37123059)
1. Recent advances in targeted therapy for pancreatic adenocarcinoma.
Fang YT; Yang WW; Niu YR; Sun YK
World J Gastrointest Oncol; 2023 Apr; 15(4):571-595. PubMed ID: 37123059
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
3. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
6. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
7. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
Kung HC; Yu J
MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Adamska A; Domenichini A; Falasca M
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson J; Ramaswamy Y; Singh G; Gorfe AA; Pavlakis N; Samra J; Mittal A; Sahni S
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456277
[TBL] [Abstract][Full Text] [Related]
12. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer.
Versemann L; Hessmann E; Ulisse M
Visc Med; 2022 Feb; 38(1):11-19. PubMed ID: 35291698
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
17. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications.
Wong KK
Cell Oncol (Dordr); 2020 Oct; 43(5):779-792. PubMed ID: 32504382
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis of pancreatic cancer: advances and challenges.
Welsch T; Kleeff J; Friess H
Curr Mol Med; 2007 Aug; 7(5):504-21. PubMed ID: 17691965
[TBL] [Abstract][Full Text] [Related]
19. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
20. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
